(Q56900194)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19236253%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

review article

1 reference

title

The monoclonal antibody to cytotoxic T lymphocyte antigen 4, ipilimumab (MDX-010), a novel treatment strategy in cancer management (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19236253%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

0 references

1 reference

1 reference

Claire F. Verschraegen

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19236253%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

author name string

Sujana Movva

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19236253%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

language of work or name

English

0 references

publication date

1 February 2009

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19236253%20AND%20SRC:MED&resulttype=core&format=json

Expert Opinion on Biological Therapy

22 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19236253%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

volume

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19236253%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19236253%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

page(s)

231-241

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19236253%20AND%20SRC:MED&resulttype=core&format=json

Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the Oblimersen Melanoma Study Group

22 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14712590802643347

High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590802643347

IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590802643347

Molecular interactions mediating T cell antigen recognition

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590802643347

The nature of molecular recognition by T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590802643347

Immunologic self-tolerance maintained by CD25(+)CD4(+) regulatory T cells constitutively expressing cytotoxic T lymphocyte-associated antigen 4.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590802643347

The emerging role of CTLA-4 as an immune attenuator

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590802643347

Complexities of CD28/B7: CTLA-4 costimulatory pathways in autoimmunity and transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590802643347

Manipulation of costimulatory signals to enhance antitumor T-cell responses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590802643347

Regulatory mechanisms of antitumor T cell responses in the tumor-bearing state

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590802643347

CTLA-4-mediated inhibition in regulation of T cell responses: mechanisms and manipulation in tumor immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590802643347

CTLA-4 can function as a negative regulator of T cell activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590802643347

CTLA-4 is a second receptor for the B cell activation antigen B7

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590802643347

A new member of the immunoglobulin superfamily--CTLA-4

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590802643347

CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590802643347

Activity and safety of CTLA-4 blockade combined with vaccines in cynomolgus macaques

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590802643347

Enhancement of antitumor immunity by CTLA-4 blockade

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590802643347

Cytotoxic T lymphocyte-associated antigen 4 plays an essential role in the function of CD25(+)CD4(+) regulatory cells that control intestinal inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590802643347

Cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) regulates the unfolding of autoimmune diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590802643347

Cutting edge: transplantation tolerance through enhanced CTLA-4 expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590802643347

Negative co-receptors on lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590802643347

Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accomp

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590802643347

CTLA-4 blockade in combination with xenogeneic DNA vaccines enhances T-cell responses, tumor immunity and autoimmunity to self antigens in animal and cellular model systems

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590802643347

Tumor regression and autoimmunity in patients treated with cytotoxic T lymphocyte-associated antigen 4 blockade and interleukin 2: a phase I/II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590802643347

Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590802643347

Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590802643347

Autoimmunity in a phase I trial of a fully human anti-cytotoxic T-lymphocyte antigen-4 monoclonal antibody with multiple melanoma peptides and Montanide ISA 51 for patients with resected stages III and IV melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590802643347

Intrapatient dose escalation of anti-CTLA-4 antibody in patients with metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590802643347

Analysis of the cellular mechanism of antitumor responses and autoimmunity in patients treated with CTLA-4 blockade

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590802643347

A pilot study of CTLA-4 blockade after cancer vaccine failure in patients with advanced malignancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590802643347

CTLA-4 control over Foxp3+ regulatory T cell function

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590802643347

Mechanisms of suppression by suppressor T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590802643347

Biologic and immunomodulatory events after CTLA-4 blockade with ticilimumab in patients with advanced malignant melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590802643347

Prognostic factors related to clinical response in patients with metastatic melanoma treated by CTL-associated antigen-4 blockade

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590802643347

A pilot trial of CTLA-4 blockade with human anti-CTLA-4 in patients with hormone-refractory prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590802643347

Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590802643347

Cytotoxic T-lymphocyte-associated antigen-4 blockage can induce autoimmune hypophysitis in patients with metastatic melanoma and renal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590802643347

Ipilimumab (anti-CTLA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590802643347

Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590802643347

Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590802643347

Review: anti-CTLA-4 antibody ipilimumab: case studies of clinical response and immune-related adverse events

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590802643347

Phase I/II study of ipilimumab for patients with metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590802643347

Durable responses and long-term progression-free survival observed in a phase II study of MDX-010 alone or in combination with dacarbazine (DTIC) in metastatic melanoma

21 January 2018

1 reference

18 October 2022

https://opencitations.net/index/coci/api/v1/citations/10.1200/JCO.2005.23.16_SUPPL.7525

Kinetics of response to ipilimumab (MDX-010) in patients with stage III/IV melanoma

1 reference

18 October 2022

https://opencitations.net/index/coci/api/v1/citations/10.1200/JCO.2007.25.18_SUPPL.8525

Identifiers

DOI

10.1517/14712590802643347

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19236253%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

1 reference